Ubrogepant Improved Patient-Reported Functional Disability and Satisfaction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
Headache 2020 Apr 01;60(4)686-700, DW Dodick, RB Lipton, J Ailani, RB Halker Singh, AR Shewale, S Zhao, JM Trugman, SY Yu, HN ViswanathanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.